Search
Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIndacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. … It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.
Quercus rubra pollen
go.drugbank.com/drugs/DB10481ApprovedQuercus rubra pollen is the pollen of the Quercus rubra plant. Quercus rubra pollen is mainly used in allergenic testing.
Mixtures: 5-oak Mix, Blackjack/bur/post/red/white PollenEfbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigational[A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid
Natamycin
go.drugbank.com/drugs/DB00826ApprovedInvestigationalAmphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]
Cetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A227963] Approved by the FDA in February 2004 under the brand name ERBITUX, cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic
Cefepime
go.drugbank.com/drugs/DB01413ApprovedInvestigational[A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as _Pseudomonas aeruginosa_, and is also indicated for the empirical
Tetracycline
go.drugbank.com/drugs/DB00759ApprovedInvestigationalVet approvedWithdrawnTetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. … It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site.
Nirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.
Drometrizole trisiloxane
go.drugbank.com/drugs/DB11585ApprovedThe compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia
Carbopol 974P
go.drugbank.com/drugs/DB05384ApprovedWithdrawnThe compound, known as BufferGel, was in advanced clinical trials for its ability to prevent pregnancy, but was discontinued. … It was under development by ReProtect LLC. It is a gel that may help both block the spread of sexually transmitted diseases and reduce unwanted pregnancies.